CASE REPORT

Feasibility of use of magnesium reabsorbable scaffolds in complex coronary artery disease: True bifurcation, multiple overlapping scaffolds and chronic total occlusion treatment

Jeremías Bayón∗, Melisa Santá-Álvarez, Raymundo Ocaranza-Sánchez, Carlos González-Juanatey

Hospital Universitario Lucus Augusti, Lugo, Galicia, Spain

Received 8 June 2017; accepted 24 August 2017

Keywords
Bioabsorbable magnesium scaffolds; Nickel allergy; Complex percutaneous coronary intervention

Abstract We present first-in-human treatment with bioabsorbable magnesium scaffolds for percutaneous coronary intervention in a patient with nickel allergy. We present images from angiography and optical coherence tomography at three months. We also review the current status of these novel devices.

© 2018 Sociedade Portuguesa de Cardiologia. Published by Elsevier España, S.L.U. All rights reserved.

Keywords
Exequibilidade de stents bioabsoríveis de magnésio na doença coronária complexa: bifurcação verdadeira, stents sobrepostos múltiplos e tratamento da oclusão crónica total

Resumo Apresentamos pela primeira vez o tratamento com suportes bioabsoríveis de magnésio na intervenção coronária percutânea complexa de doentes com alergia ao níquel. Incluímos a angiografia e as imagens da tomografia de coerência óptica efetuadas durante um período de três meses. Analisamos também o estado atual deste equipamento inovador.

© 2018 Sociedade Portuguesa de Cardiologia. Publicado por Elsevier España, S.L.U. Todos os direitos reservados.

* Corresponding author.
E-mail address: jerebayon@gmail.com (J. Bayón).

2174-2049/© 2018 Sociedade Portuguesa de Cardiologia. Published by Elsevier España, S.L.U. All rights reserved.
Introduction

The Magmaris bioabsorbable sirolimus-releasing magnesium scaffold (Biotronik) is the first device of its kind that is clinically tested and with proven safety data. It features a metallic magnesium backbone with corrugated ring design, six crowns and strut thickness of \(150 \times 150 \mu\)m. In vitro tests have demonstrated greater radial strength, 20% less recoil and 80% more flexibility than the Absorb bioabsorbable sirolimus-releasing polymeric acid (PLLA) scaffold (Abbott).1

The magnesium backbone is coated with a compound called BIClute, a resorbable PLLA polymer which delivers controlled release of the sirolimus drug for up to 90 days and which is metabolized in the body to carbon dioxide and water. The absorption process is rapid, with 95% of the magnesium being reabsorbed within twelve months.2

A safety study, BIOSOLVE I, enrolled 46 patients with de novo coronary lesions. Three-year follow-up results were obtained from 44 patients, which showed target lesion failure in three cases (6.6%), and no cardiac death or device thrombosis. Seven patients had additional angiographic follow-up at \(28 \pm 4\) months: in-scaffold late luminal loss had improved from \(0.51 \pm 0.46\) mm (median 0.28 mm) at 12 months to \(0.32 \pm 0.32\) mm (median 0.20 mm).3

The 12-month results of BIOSOLVE-II have recently been published, enrolling 123 patients with de novo lesions with a reference diameter between 2.2 mm and 3.7 mm. Quantitative coronary angiography parameters were stable from 6 to 12 months (paired data of 42 patients: in-segment late lumen loss \(0.20 \pm 0.21\) mm vs. \(0.25 \pm 0.22\) mm, \(p=0.117\); in-scaffold late lumen loss \(0.37 \pm 0.25\) mm vs. \(0.39 \pm 0.27\) mm, \(p=0.446\), respectively. Intravascular ultrasound demonstrated preserved minimal luminal area at six months \((6.24 \pm 1.15 \text{ mm}^2)\) after percutaneous coronary intervention [PCI] vs. \(6.21 \pm 1.22 \text{ mm}^2\) at six months), with a small neointimal area \((0.08 \pm 0.09 \text{ mm}^2)\). Optical coherence tomography (OCT) detected no intraluminal masses. Target lesion failure was observed in 3.4%, with no definite or probable scaffold thrombosis.4

Current recommendations for the Magmaris implant are de novo coronary lesions with a vessel diameter near the nominal size of the scaffold and a length shorter than the device. Among lesions not recommended or those in which special care has to be taken are total chronic occlusion, excessive tortuosity and side branches (bifurcations) greater than 2 mm in diameter.5

Case report

We present the case of a 65-year-old male with nickel allergy who was admitted to the hospital with non-ST-elevation acute coronary syndrome. Coronary angiography showed significant two-vessel coronary disease not suitable for surgical revascularization because of small caliber and diffuse disease. There were multiple tandem lesions from the proximal to the distal left anterior descending (LAD) artery, bifurcated (Medina 1,1,1) with a diagonal branch, and a chronic total occlusion (CTO) in the mid circumflex (CX) (Figure 1).

The patient was on aspirin so a loading dose of 180 mg ticagrelor was added. For the coronary angiography 8000 U heparin (weight-adjusted) and 300 µg intracoronary nitroglycerine were administered, in order to obtain a better assessment of the actual size of the coronary arteries. No imaging techniques were performed because of difficulty in crossing the lesion.

The LAD was treated, first with predilatation with a \(3.0 \times 20\) mm non-complaint balloon in the distal LAD and the diagonal branch, and a \(3.5 \times 20\) mm balloon in the proximal LAD (balloon-scaffold ratio 1:1). Sequential

![Figure 1](image.png)  
**Figure 1**  Coronary angiography at baseline, post-percutaneous intervention with implantation of Magmaris devices, and follow-up at three months. CX: circumflex; LAD: left anterior descending.
Feasibility

Partial
daily
with
(Reverse
Philips)
One
highlight
treated
diameter
cation
We
sirolimus-releasing
Conclusion
Three-month
consent,
12
months,
which
two
implanted
is leaving 1 mm between the devices) from the distal LAD
(one 3 mm × 15 mm and two 3.5 mm × 25 mm) to the bifurcation
with the diagonal. StentBoost image enhancement
(Philips) was used to adjust the overlap. Two more Magmaris
scaffolds were then implanted in the median LAD
(3.5 mm × 25 mm) and the diagonal (3 mm × 15 mm) by the
reverse T and protrusion technique. The CTO of the CX was
treated with a 3 mm × 25 mm Magmaris. The scaffolds were
implanted according to the manufacturer’s recommendations
to adequately predilate the lesion, select a device
diameter very similar to vessel size, and postdilate without
exceeding 0.6 mm above the nominal size of the device
(Figure 1). In this case, we used non-compliant balloons with
a 1:1 ratio except for the scaffold in the proximal LAD,
which was postdilated with a 4.0 mm × 20 mm non-compliant
balloon. The final result was confirmed by OCT.

The patient was discharged with recommendation for
12 months dual antiplatelet therapy with aspirin 100 mg
daily and ticagrelor 90 mg twice daily.

At three months, with no symptoms and with the patient’s
consent, coronary angiography was repeated (Figure 1).
Three-month OCT showed appropriate strut apposition and
partial covering of the majority of the struts (Figure 2).

Conclusion

We present first-in-human complex PCI in a patient
with nickel allergy treated with Magmaris bioabsorbable
sirolimus-releasing magnesium scaffolds (Biotronik). We
highlight the good apposition in the CTO lesion and the true
bifurcation and overlapping in the LAD, with good results on
OCT. This novel device is becoming a real option in these
patients.

Conflicts of interest

The authors have no conflicts of interest to declare.

References

patients with de novo coronary lesions: 3-year results of the prospective, multicentre, first-in-man BIOSOLVE-I trial. EuroInter-
scaffold in patients with de novo coronary lesions: 12-month clinical results and angiographic findings of the BIOSOLVE-II first-